160 related articles for article (PubMed ID: 12629580)
1. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.
Holthe M; Rakvåg TN; Klepstad P; Idle JR; Kaasa S; Krokan HE; Skorpen F
Pharmacogenomics J; 2003; 3(1):17-26. PubMed ID: 12629580
[TBL] [Abstract][Full Text] [Related]
2. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.
Duguay Y; Báár C; Skorpen F; Guillemette C
Clin Pharmacol Ther; 2004 Mar; 75(3):223-33. PubMed ID: 15001974
[TBL] [Abstract][Full Text] [Related]
3. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
Innocenti F; Iyer L; Ramírez J; Green MD; Ratain MJ
Drug Metab Dispos; 2001 May; 29(5):686-92. PubMed ID: 11302935
[TBL] [Abstract][Full Text] [Related]
4. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.
Fladvad T; Klepstad P; Langaas M; Dale O; Kaasa S; Caraceni A; Skorpen F
Pharmacogenet Genomics; 2013 Mar; 23(3):117-26. PubMed ID: 23277092
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.
Court MH; Krishnaswamy S; Hao Q; Duan SX; Patten CJ; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Sep; 31(9):1125-33. PubMed ID: 12920168
[TBL] [Abstract][Full Text] [Related]
6. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
7. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the effect of UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A9 genetic polymorphisms on enantioselective glucuronidation of flurbiprofen.
Wang H; Yuan L; Zeng S
Biochem Pharmacol; 2011 Dec; 82(11):1757-63. PubMed ID: 21856293
[TBL] [Abstract][Full Text] [Related]
9. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.
Darbari DS; van Schaik RH; Capparelli EV; Rana S; McCarter R; van den Anker J
Am J Hematol; 2008 Mar; 83(3):200-2. PubMed ID: 17724700
[TBL] [Abstract][Full Text] [Related]
10. Homo- and hetero-dimerization of human UDP-glucuronosyltransferase 2B7 (UGT2B7) wild type and its allelic variants affect zidovudine glucuronidation activity.
Yuan L; Qian S; Xiao Y; Sun H; Zeng S
Biochem Pharmacol; 2015 May; 95(1):58-70. PubMed ID: 25770680
[TBL] [Abstract][Full Text] [Related]
11. The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
Yang ZZ; Li L; Wang L; Yuan LM; Xu MC; Gu JK; Jiang HD; Yu LS; Zeng S
Acta Pharmacol Sin; 2017 Aug; 38(8):1184-1194. PubMed ID: 28552915
[TBL] [Abstract][Full Text] [Related]
12. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
Innocenti F; Liu W; Fackenthal D; Ramírez J; Chen P; Ye X; Wu X; Zhang W; Mirkov S; Das S; Cook E; Ratain MJ
Pharmacogenet Genomics; 2008 Aug; 18(8):683-97. PubMed ID: 18622261
[TBL] [Abstract][Full Text] [Related]
13. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy.
Hirota T; Ieiri I; Takane H; Sano H; Kawamoto K; Aono H; Yamasaki A; Takeuchi H; Masada M; Shimizu E; Higuchi S; Otsubo K
Drug Metab Dispos; 2003 May; 31(5):677-80. PubMed ID: 12695358
[TBL] [Abstract][Full Text] [Related]
14. Human UGT2B7 catalyzes morphine glucuronidation.
Coffman BL; Rios GR; King CD; Tephly TR
Drug Metab Dispos; 1997 Jan; 25(1):1-4. PubMed ID: 9010622
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter.
Hu DG; Meech R; Lu L; McKinnon RA; Mackenzie PI
Drug Metab Dispos; 2014 May; 42(5):854-62. PubMed ID: 24561451
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in the 5'-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation.
Nakamura A; Nakajima M; Higashi E; Yamanaka H; Yokoi T
Pharmacogenet Genomics; 2008 Aug; 18(8):709-20. PubMed ID: 18622263
[TBL] [Abstract][Full Text] [Related]
17. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4.
Takeda S; Ishii Y; Iwanaga M; Mackenzie PI; Nagata K; Yamazoe Y; Oguri K; Yamada H
Mol Pharmacol; 2005 Mar; 67(3):665-72. PubMed ID: 15611481
[TBL] [Abstract][Full Text] [Related]
18. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter.
Ishii Y; Hansen AJ; Mackenzie PI
Mol Pharmacol; 2000 May; 57(5):940-7. PubMed ID: 10779377
[TBL] [Abstract][Full Text] [Related]
19. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver.
Mano Y; Usui T; Kamimura H
Drug Metab Dispos; 2007 Nov; 35(11):2040-4. PubMed ID: 17670842
[TBL] [Abstract][Full Text] [Related]
20. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
